Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease

Matthew J. Johnson, Kanut Laoharawee, Walker S. Lahr, Beau R. Webber, Branden S. Moriarity

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

B cells offer unique opportunities for gene therapy because of their ability to secrete large amounts of protein in the form of antibody and persist for the life of the organism as plasma cells. Here, we report optimized CRISPR/Cas9 based genome engineering of primary human B cells. Our procedure involves enrichment of CD19+ B cells from PBMCs followed by activation, expansion, and electroporation of CRISPR/Cas9 reagents. We are able expand total B cells in culture 10-fold and outgrow the IgD+ IgM+ CD27− naïve subset from 35% to over 80% of the culture. B cells are receptive to nucleic acid delivery via electroporation 3 days after stimulation, peaking at Day 7 post stimulation. We tested chemically modified sgRNAs and Alt-R gRNAs targeting CD19 with Cas9 mRNA or Cas9 protein. Using this system, we achieved genetic and protein knockout of CD19 at rates over 70%. Finally, we tested sgRNAs targeting the AAVS1 safe harbor site using Cas9 protein in combination with AAV6 to deliver donor template encoding a splice acceptor-EGFP cassette, which yielded site-specific integration frequencies up to 25%. The development of methods for genetically engineered B cells opens the door to a myriad of applications in basic research, antibody production, and cellular therapeutics.

Original languageEnglish (US)
Article number12144
JournalScientific reports
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
Human Engineering
B-Lymphocytes
Electroporation
Proteins
Guide RNA
Immunoglobulin D
Aptitude
Plasma Cells
Genetic Therapy
Nucleic Acids
Antibody Formation
Immunoglobulin M
Cell Culture Techniques
Genome
Messenger RNA
Antibodies
Research

Cite this

Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease. / Johnson, Matthew J.; Laoharawee, Kanut; Lahr, Walker S.; Webber, Beau R.; Moriarity, Branden S.

In: Scientific reports, Vol. 8, No. 1, 12144, 01.12.2018.

Research output: Contribution to journalArticle

@article{82b631704b7448ce9a976ca120608eac,
title = "Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease",
abstract = "B cells offer unique opportunities for gene therapy because of their ability to secrete large amounts of protein in the form of antibody and persist for the life of the organism as plasma cells. Here, we report optimized CRISPR/Cas9 based genome engineering of primary human B cells. Our procedure involves enrichment of CD19+ B cells from PBMCs followed by activation, expansion, and electroporation of CRISPR/Cas9 reagents. We are able expand total B cells in culture 10-fold and outgrow the IgD+ IgM+ CD27− na{\"i}ve subset from 35{\%} to over 80{\%} of the culture. B cells are receptive to nucleic acid delivery via electroporation 3 days after stimulation, peaking at Day 7 post stimulation. We tested chemically modified sgRNAs and Alt-R gRNAs targeting CD19 with Cas9 mRNA or Cas9 protein. Using this system, we achieved genetic and protein knockout of CD19 at rates over 70{\%}. Finally, we tested sgRNAs targeting the AAVS1 safe harbor site using Cas9 protein in combination with AAV6 to deliver donor template encoding a splice acceptor-EGFP cassette, which yielded site-specific integration frequencies up to 25{\%}. The development of methods for genetically engineered B cells opens the door to a myriad of applications in basic research, antibody production, and cellular therapeutics.",
author = "Johnson, {Matthew J.} and Kanut Laoharawee and Lahr, {Walker S.} and Webber, {Beau R.} and Moriarity, {Branden S.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-30358-0",
language = "English (US)",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease

AU - Johnson, Matthew J.

AU - Laoharawee, Kanut

AU - Lahr, Walker S.

AU - Webber, Beau R.

AU - Moriarity, Branden S.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - B cells offer unique opportunities for gene therapy because of their ability to secrete large amounts of protein in the form of antibody and persist for the life of the organism as plasma cells. Here, we report optimized CRISPR/Cas9 based genome engineering of primary human B cells. Our procedure involves enrichment of CD19+ B cells from PBMCs followed by activation, expansion, and electroporation of CRISPR/Cas9 reagents. We are able expand total B cells in culture 10-fold and outgrow the IgD+ IgM+ CD27− naïve subset from 35% to over 80% of the culture. B cells are receptive to nucleic acid delivery via electroporation 3 days after stimulation, peaking at Day 7 post stimulation. We tested chemically modified sgRNAs and Alt-R gRNAs targeting CD19 with Cas9 mRNA or Cas9 protein. Using this system, we achieved genetic and protein knockout of CD19 at rates over 70%. Finally, we tested sgRNAs targeting the AAVS1 safe harbor site using Cas9 protein in combination with AAV6 to deliver donor template encoding a splice acceptor-EGFP cassette, which yielded site-specific integration frequencies up to 25%. The development of methods for genetically engineered B cells opens the door to a myriad of applications in basic research, antibody production, and cellular therapeutics.

AB - B cells offer unique opportunities for gene therapy because of their ability to secrete large amounts of protein in the form of antibody and persist for the life of the organism as plasma cells. Here, we report optimized CRISPR/Cas9 based genome engineering of primary human B cells. Our procedure involves enrichment of CD19+ B cells from PBMCs followed by activation, expansion, and electroporation of CRISPR/Cas9 reagents. We are able expand total B cells in culture 10-fold and outgrow the IgD+ IgM+ CD27− naïve subset from 35% to over 80% of the culture. B cells are receptive to nucleic acid delivery via electroporation 3 days after stimulation, peaking at Day 7 post stimulation. We tested chemically modified sgRNAs and Alt-R gRNAs targeting CD19 with Cas9 mRNA or Cas9 protein. Using this system, we achieved genetic and protein knockout of CD19 at rates over 70%. Finally, we tested sgRNAs targeting the AAVS1 safe harbor site using Cas9 protein in combination with AAV6 to deliver donor template encoding a splice acceptor-EGFP cassette, which yielded site-specific integration frequencies up to 25%. The development of methods for genetically engineered B cells opens the door to a myriad of applications in basic research, antibody production, and cellular therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85053422250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053422250&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-30358-0

DO - 10.1038/s41598-018-30358-0

M3 - Article

C2 - 30108345

AN - SCOPUS:85053422250

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 12144

ER -